# Study of Adjuvant Nimotuzumab Combined with Nab-paclitaxel+ Gemcitabine in EGFR-positive Pancreatic Cancer

> **NCT06722911** · PHASE2 · RECRUITING · sponsor: **Zhejiang Provincial People's Hospital** · enrollment: 57 (estimated)

## Conditions studied

- Pancreatic Cancer Resectable

## Interventions

- **DRUG:** Nimotuzumab
- **DRUG:** AG

## Key facts

- **NCT ID:** NCT06722911
- **Lead sponsor:** Zhejiang Provincial People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-15
- **Primary completion:** 2028-09-30
- **Final completion:** 2028-09-30
- **Target enrollment:** 57 (ESTIMATED)
- **Last updated:** 2024-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06722911

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06722911, "Study of Adjuvant Nimotuzumab Combined with Nab-paclitaxel+ Gemcitabine in EGFR-positive Pancreatic Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06722911. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*